Search
Close this search box.

Recursion Expands Its Presence with a New London Office and Bolsters Scientific Advisory Team

Recursion (NASDAQ: RXRX), a clinical-stage TechBio company, has unveiled plans to establish a new office in London’s King’s Cross area, aiming to tap into the European pool of TechBio talent.

This move is part of Recursion’s efforts to decode biology and streamline the drug discovery process. The new office, scheduled to open in June 2024, will join the company’s artificial intelligence research engine, Valence Labs, in benefiting from the dynamic European TechBio sector.

The selection of London as the location for its new office is a testament to the city’s reputation as a nexus for interdisciplinary talent in technology, biology, and chemistry. Chris Gibson, Ph.D., co-founder and CEO of Recursion, emphasized the importance of hiring exceptional talent, much of which is located in Europe. London’s vibrant TechBio sector, proximity to leading technology and life science companies, and its role as a center for innovation made it an ideal choice for Recursion’s expansion.

RELATED: Tech-First Companies Take the Lead in AI Drug Discovery

In conjunction with its London expansion, Recursion is delighted to announce the appointment of Michael Bronstein, a DeepMind Professor of Artificial Intelligence at Oxford University, as a Scientific Advisor. Professor Bronstein, renowned for his work in geometric deep learning, graph neural networks, and protein design, joins the esteemed AI expert Professor Yoshua Bengio in guiding Recursion and Valence Labs. This collaboration underscores Recursion’s commitment to leveraging cutting-edge AI research for drug discovery.

The new office, covering 6,700 square feet at 3 Pancras Square, is part of a comprehensive redevelopment project in King’s Cross. With its strategic location, sustainable building standards, and comprehensive amenities, the office aligns with Recursion’s dedication to sustainability and employee well-being.

The UK Government has welcomed Recursion’s investment as a significant endorsement of the UK’s tech and life sciences sectors. Investment Minister Lord Johnson expressed enthusiasm for Recursion’s choice of London, highlighting the government’s efforts to attract inward investment and maintain the UK’s attractiveness for the tech and life science industries.

Recursion, which currently employs over 500 individuals across various locations, including Salt Lake City, Toronto, Montréal, and the San Francisco Bay Area, views the London office as an extension of its team. The company has initiated recruitment for the first 20 roles at the new location, signaling a robust effort to attract top talent in technology and biology.

The company’s mission is supported by the Recursion OS, a platform that leverages machine learning to analyze one of the world’s largest proprietary datasets in biology, chemistry, and patient-centric data. This approach allows Recursion to conduct large-scale wet lab experiments and computational analyses, propelling the company forward in its quest to transform the future of medicine.

Topics:
Biotech Companies